♥ HF Guideline NavigatorESC 2026

5 › 5.3 › 5.3.1

5.3.1 Cardiac imaging: multimodality approach

Pages 28–29 · open in PDF

Recommendations in this section

  • Class ILevel CContrast-enhanced CMR is recommended in patients with suspected cardiomyopathy, or where the underlying aetiology of HF is uncertain if further characterization is likely to add value to patient care.
  • Class ILevel BInitial diagnostic testing with serum and urine immunofixation, serum free light chains assay, and DPD/PYP/HMDP bone scintigraphy is recommended in patients with HF and a suspicion of cardiac amyloidosis.
  • Class ILevel CGenetic testing is recommended in patients fulfilling diagnostic criteria for cardiomyopathy in cases where it enables diagnosis, prognostication, therapeutic stratification, or reproductive management of the patient, or where it enables cascade genetic evaluation of their relatives who would otherwise be enrolled into long-term surveillance.
  • Class ILevel CInvasive coronary angiography is recommended in patients with HF, angina, and high probability of obstructive CAD who are potential candidates for revascularization.
  • Class IIaLevel C18F-FDG-PET scanning should be considered for the diagnostic work-up in patients with cardiomyopathy in whom cardiac sarcoidosis is suspected.
  • Class IIaLevel CEndomyocardial biopsy should be considered to aid in diagnosis and management in patients with rapidly progressive HF despite standard therapy or when the results of other clinical investigations suggest myocardial inflammation, infiltration, or storage that cannot be identified by other means.
  • Class IIaLevel CRight heart catheterization should be considered in patients where HF is thought to be due to constrictive pericarditis or congenital heart disease.
  • Class IIbLevel CRight heart catheterization may be considered in selected patients with suspected HFpEF or structural heart disease to confirm the diagnosis, or when clinical examination and non-invasive testing are insufficient to understand the haemodynamic state.
  • Class IIaLevel CInvasive coronary angiography should be considered in patients with HFrEF and high pre-test likelihood of obstructive CAD, taking into account the risk-to-benefit ratio of the procedures and potential revascularization strategies.
  • Class IIaLevel CCTCA should be considered in patients with HFrEF and low-moderate pre-test likelihood of obstructive CAD.
  • Class IIaLevel CReview of the proportion of RV pacing should be considered in all patients with CIED and de novo or worsening HFrEF.
  • Class IIbLevel CElectrical cardioversion as a diagnostic tool may be considered in patients with persistent AF where there is uncertainty about the value of sinus rhythm restoration on symptoms or to assess improvement in left ventricular function.

Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.

Page 28 · PDF

cardiac sarcoidosis (see Supplementary data online, Table S2).181,182 Genetic testing may be appropriate when a genetic cause is suspected and the results may provide management and prognostic guidance, result in cascade family screening or reproductive management. For more specific guidance on genetic testing in specific cardiomyopathies, we refer to the 2023 ESC Guidelines for the management of cardiomyopathies.48,124

Multimodal cardiac imaging plays a pivotal role in the diagnosis, management, and prognostic assessment of HF, enabling precise subtyping to aid in disease-specific therapy selection and is supported by a growing body of evidence (Figure 7).

      

   €   ‚        

Figure 7 Multiparametric approach to aetiology assessment in heart failure. 18F-FDG-PET, 18F-fluorodeoxyglucose-positron emission tomography; CMR, cardiac magnetic resonance; CTCA, computed tomography coronary angiography; DPD, 3,3-diphosphono1,2-propanodicarboxylic acid; ECG, electrocardiogram; EMB, endomyocardial biopsy; HMPD, hydroxymethylene diphosphonate; ICA, invasive coronary angiography; PYP, pyrophosphate; RHC, right heart catheterization.

5.3.1. Cardiac imaging in heart failure: a multimodality approach

Echocardiography is considered the first-line imaging modality in HF and remains the cornerstone of assessment. Echocardiography has widespread availability, is noninvasive, and provides the ability for real-time dynamic evaluation of cardiac structures, dimensions, volumes, filling patterns, haemodynamics, and function. Tissue Doppler imaging and speckle-tracking echocardiography have allowed clinicians to quantify myocardial global longitudinal strain, offering more sensitive measures of early systolic dysfunction even before LVEF declines, which is of particular value in patients undergoing chemotherapy, or specific strain patterns that may be suggestive of amyloidosis or HCM.183–185 In patients with HFpEF, diastolic stress testing is emerging as an important tool to unmask diastolic dysfunction that may not be apparent at rest. Depending on echocardiography findings, additional imaging modalities or

Page 29 · PDF

(Figure 8). For frail patients, a typical medical history of angina accompanied by echocardiography showing coronary territory scarring or regional wall motion abnormalities may suffice. In patients with potential for revascularization, further examinations may be needed, considering individual risks and benefits. Computed tomography coronary angiography (CTCA) has a high negative predictive value and should be considered in patients with HF when the likelihood of CAD is low to moderate.196 If patients are possible candidates for revascularization, invasive coronary angiography (ICA) is indicated in patients with HFrEF with a high likelihood of CAD and in patients with angina, regardless of LVEF. Computed tomography coronary angiography and ICA should be used with caution in patients with eGFR <30 mL/ min/1.73 m2 and/or contraindication for contrast medium administration. Evidence supporting the efficacy of viability testing to identify suitable patients for revascularization is lacking.178,179

5.3.2. Investigations for coronary artery disease

5.3.3. Heart failure caused by arrhythmia or conduction disease

Coronary artery disease is highly prevalent in HF and the most common cause of HFrEF.13,33,195 Even though assessment of aetiology is essential in HF, investigations for CAD should be tailored to the individual patient’s risks and benefits

Arrhythmia-associated HF is a broad term that encompasses HF caused by tachyarrhythmias, including AF, atrial flutter, other supraventricular tachycardias, ventricular tachycardia, and premature ventricular contraction (PVC).197,198 The identification

Figure 8 Diagnosis of heart failure due to ischaemic aetiology. CAD, coronary artery disease; CMR, cardiac magnetic resonance; CTCA,

computed tomography coronary angiography; CV, cardiovascular; HF, heart failure; LV, left ventricular. aStress tests include stress echocardiography, stress CMR, or nuclear imaging. Electrocardiographic exercise test has not been shown to properly assess coronary stress.

testing may be needed (see Supplementary data online, Table S2). Advances in multimodal imaging, including CMR, stress testing, and computed tomography (CT), have significantly enhanced our capacity to comprehensively assess HF, offering complementary information that is crucial in complex cases.183–185 CMR is considered the gold standard for assessing LV volumes and mass, owing to its high spatial resolution and reproducibility. Late gadolinium enhancement (LGE) provides detailed insights into fibrosis and scarring and is useful in distinguishing ischaemic from non-ischaemic aetiology as well as certain cardiomyopathies.124 CMR myocardial tissue characterization with parametric mapping [T1, T2, T2* (longitudinal, transverse, and observed transverse relaxation times), LGE and extracellular volume (ECV) expansion] enables classification of cardiomyopathies124,186–193 and of cardiac amyloid.194 An overview of typical CMR findings in cardiomyopathies can be found in the 2023 ESC Guidelines for the management of cardiomyopathies.124 Description of other specific imaging modalities is provided in the Sections on specific comorbidities.